Jeffrey L. Bennett, Sean J. Pittock, Friedemann Paul, Ho Jin Kim, Sarosh R. Irani, Kevin C. O'Connor, Kristina R. Patterson, Michael A. Smith, Michele Gunsior, Nanette Mittereder, William A. Rees, Daniel Cimbora, Bruce A. C. Cree
{"title":"B 细胞和水通道蛋白-4 抗体与神经脊髓炎视谱系障碍活动的关系。","authors":"Jeffrey L. Bennett, Sean J. Pittock, Friedemann Paul, Ho Jin Kim, Sarosh R. Irani, Kevin C. O'Connor, Kristina R. Patterson, Michael A. Smith, Michele Gunsior, Nanette Mittereder, William A. Rees, Daniel Cimbora, Bruce A. C. Cree","doi":"10.1002/acn3.52171","DOIUrl":null,"url":null,"abstract":"<p>This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20<sup>+</sup> and CD27<sup>+</sup> B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (<i>p</i> = 0.016) and from baseline to attack (<i>p</i> = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed.</p>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52171","citationCount":"0","resultStr":"{\"title\":\"B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity\",\"authors\":\"Jeffrey L. Bennett, Sean J. Pittock, Friedemann Paul, Ho Jin Kim, Sarosh R. Irani, Kevin C. O'Connor, Kristina R. Patterson, Michael A. Smith, Michele Gunsior, Nanette Mittereder, William A. Rees, Daniel Cimbora, Bruce A. C. Cree\",\"doi\":\"10.1002/acn3.52171\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20<sup>+</sup> and CD27<sup>+</sup> B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (<i>p</i> = 0.016) and from baseline to attack (<i>p</i> = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed.</p>\",\"PeriodicalId\":126,\"journal\":{\"name\":\"Annals of Clinical and Translational Neurology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.52171\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Clinical and Translational Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acn3.52171\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Translational Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acn3.52171","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
这项伊维单抗治疗神经性脊髓炎视网膜频谱紊乱症(NMOSD)的随机安慰剂对照 N-MOmentum 研究(NCT02200770)的事后分析评估了循环 B 细胞亚群和水通道蛋白-4 免疫球蛋白 G (AQP4-lgG) 滴度与发作之间的关系。在接受安慰剂治疗的参与者中,CD20+和CD27+ B细胞计数从发作前到发作期间略有增加;浆细胞/浆细胞基因特征从基线到发作前(p = 0.016)以及从基线到发作期间(p = 0.009)均有所增加。接受伊匹单抗治疗后,B细胞亚群数量减少,且不随发作而增加。从基线到发病时,AQP4-IgG滴度的变化无差异。
B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity
This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20+ and CD27+ B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (p = 0.016) and from baseline to attack (p = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed.
期刊介绍:
Annals of Clinical and Translational Neurology is a peer-reviewed journal for rapid dissemination of high-quality research related to all areas of neurology. The journal publishes original research and scholarly reviews focused on the mechanisms and treatments of diseases of the nervous system; high-impact topics in neurologic education; and other topics of interest to the clinical neuroscience community.